Certara (NASDAQ:CERT) Updates FY24 Earnings Guidance

Certara (NASDAQ:CERT) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $0.41-0.44 for the period, compared to the consensus earnings per share estimate of $0.41. The company issued revenue guidance of $380-385 million, compared to the consensus revenue estimate of $386.66 million. Certara also updated its FY 2024 guidance to 0.410-0.440 EPS.

Certara Trading Up 5.8 %

Shares of Certara stock traded up $0.60 on Wednesday, reaching $10.91. The company had a trading volume of 1,177,404 shares, compared to its average volume of 779,711. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -21.82, a P/E/G ratio of 4.88 and a beta of 1.51. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The firm’s 50-day moving average price is $11.10 and its two-hundred day moving average price is $13.77. Certara has a 1 year low of $9.99 and a 1 year high of $19.87.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The firm had revenue of $93.31 million for the quarter, compared to analysts’ expectations of $96.01 million. During the same period in the previous year, the firm earned $0.10 earnings per share. The firm’s quarterly revenue was up 3.2% compared to the same quarter last year. As a group, research analysts predict that Certara will post 0.27 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Robert W. Baird cut their price target on shares of Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday. KeyCorp cut their target price on Certara from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Barclays decreased their price target on Certara from $16.00 to $14.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 15th. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Friday, September 27th. Finally, JMP Securities reiterated a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $16.25.

Insider Buying and Selling at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Leif E. Pedersen sold 51,224 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares in the company, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at $552,503.73. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 2.39% of the stock is currently owned by corporate insiders.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.